Evaxion presents new preclinical data for CMV vaccine program EVX-V1
EVAX•Preclinical CMV vaccine data presented at herpesvirus workshop
Evaxion reported new preclinical data supporting its CMV vaccine program EVX-V1, highlighting improved control of acute infection, latency and viral reactivation in mice.
- Findings support EVX-V1’s multi-component design combining AI-discovered antigens with AI-optimized versions of established CMV vaccine antigens.
- Data were presented in a poster session at the International Herpesvirus Workshop 2026 in Montreal.
